Adults Now Drive Growth of Vaccine Market

[Guest guest]

http://www.genengnews.com/articles/chitem.aspx?aid=2490

Jun 1 2008 (Vol. 28, No. 11)

Adults Now Drive Growth of Vaccine Market

Success of Merck's Gardasil Is Responsible for

the Large Increase Seen in this Sector

Bruce Carlson

For much of the 20th century, vaccines were a

pharmaceutical success story largely associated

with children. Aggressive immunization programs

eradicated polio and smallpox in developed

nations and nearly eliminated mumps, pertussis,

measles, and other diseases. While immunization

of the young is still a health priority worldwide

and pediatric vaccines an important market, it is

now adults who are fueling the growth of vaccine products.

Adults are as likely as children to die from

diseases that they can be immunized against. For

example, vaccines can prevent about 50% of deaths

from pneumococcal disease and 80% of deaths from

influenza-related complications in the elderly.

Public-policy programs and pharmaceutical

industry marketing seem to be finally catching up with this reality.

Kalorama Information estimates that 2007 was the

first year that adult vaccine sales overtook

pediatric sales, just slightly but significantly

nonetheless. Adult vaccines represented 44% of

total vaccine sales in 2006. By 2007, sales

attributed to adult doses rose to 50.6% of

vaccine sales. This surprising development can be

attributed to robust sales of a group of

influenza vaccines and the success of one

product­Merck & Co.’s Gardasil for the HPV virus,

which posted sales of $1.5 billion in 2007.

World sales of adult vaccines exceeded $8.2

billion in 2007, increasing 51.0% over 2006 sales

of $5.4 billion. Sales of adult vaccines are

projected to increase at a compound annual rate

of 12.0% from 2008 to 2013 and reach $17.6 billion in 2013.

Last year’s result could be written off as a

one-time occurrence explained by the higher cost

of adult vaccines (Gardasil carries an estimated

price tag of $300–$500), and indeed adult

vaccines are not expected to maintain the

leadership position as competition and volume

reduce adult vaccine prices. Yet the sudden show

of strength by the adult segment portends a

future where the segments will roughly equal out.

The success of Gardasil and adult influenza

vaccines has not only shaken up the market

place­vaulting Merck from an estimated fourth

place to a leadership role in the vaccine market

in two years­but it has also created a tremendous

opportunity for vaccine marketing. It is likely

that the pharmaceutical industry will look to new

adult vaccines for the next blockbuster drug.

This may result in products in disease areas that

were not treated by vaccines in the past.

In 2007, the world market for preventive vaccines

totaled $16.3 billion, up more than 38% from

$11.7 billion in 2006. The market is predicted to

increase at a compound annual rate of 13.1%

during 2008. This growth rate is unheard of in

other drug categories, especially since this is

expected to be a challenging year for the

pharmaceutical industry. Few other drug

categories will see as many new product

introductions and such public-policy attention.

The world vaccines market is dominated by five

companies: Merck & Co., GlaxoKline, Sanofi

Pasteur, Wyeth, and Novartis. The four largest

firms, whose reported vaccine sales exceeded $2

billion each in 2007, held a combined 91.5% of the market.

In 2007, Merck was the leading competitor with

26.2% market share, followed closely by Sanofi

Pasteur with 25.9% and GlaxoKline with

24.2%. Wyeth followed at a distance with 15.2%,

while Novartis held at 5.8%. In 2007, Novartis

reported strong growth in its new vaccines and

diagnostics division, with total sales of almost

$1.5 billion on expanded usage of vaccines for

tick-borne encephalitis, seasonal influenza, and pediatric immunizations.

Pediatric Vaccines

While adult vaccine revenues have grown more

dramatically, there has been no letdown in sales

of pediatric vaccines. Increased vaccination and

new products will continue to drive growth in this category.

Global vaccination rates will continue to rise,

but wide discrepancies will remain from region to

region. In 2007, almost 30 million infants

worldwide had not been vaccinated against DPT3,

with 75% of those living in India, China,

Nigeria, Indonesia, Pakistan, Ethiopia, Congo,

Sudan, Bangladesh, and the Philippines.

In 2007, global sales of pediatric vaccines

exceeded $8.0 billion, an increase of 25.2% over

2006 sales of $6.3 billion. This high growth was

due in part to continued heavy gains of Wyeth’s

pneumococcal vaccine, Prevnar during the year, as

well as the introduction of Merck’s, RotaTeq.

From 2007 to 2012, sales of Prevnar are expected

to follow a more moderate growth rate, although

new pneumococcal vaccines will be introduced that

could stimulate further gains. This will result

in an overall market expansion of 14.2% per year

from 2008 to 2013, with total sales reaching

$18.8 billion at the end of the forecast period.

--------------------------------------------------------

Sheri Nakken, former R.N., MA, Hahnemannian Homeopath

Vaccination Information & Choice Network, Nevada City CA & Wales UK

Vaccines - http://www.wellwithin1.com/vaccine.htm

Vaccine Dangers & Homeopathy Online/email courses

[Guest guest]

Hmm, maybe the sales of pediatric vaccines aren't such a sure thing now that the

truth is coming out about the dangers.

Winnie

Adults Now Drive Growth of Vaccine Market

Recipient list suppressed: ;

> http://www.genengnews.com/articles/chitem.aspx?aid=2490

>

> Jun 1 2008 (Vol. 28, No. 11)

>

>

> Adults Now Drive Growth of Vaccine Market

>

>

>

>

> Success of Merck's Gardasil Is Responsible for

> the Large Increase Seen in this Sector

>

>

>

>

> Bruce Carlson

>

> For much of the 20th century, vaccines were a

> pharmaceutical success story largely associated

> with children. Aggressive immunization programs

> eradicated polio and smallpox in developed

> nations and nearly eliminated mumps, pertussis,

> measles, and other diseases. While immunization

> of the young is still a health priority worldwide

> and pediatric vaccines an important market, it is

> now adults who are fueling the growth of vaccine products.

>

> Adults are as likely as children to die from

> diseases that they can be immunized against. For

> example, vaccines can prevent about 50% of deaths

> from pneumococcal disease and 80% of deaths from

> influenza-related complications in the elderly.

> Public-policy programs and pharmaceutical

> industry marketing seem to be finally catching up with this reality.

>

> Kalorama Information estimates that 2007 was the

> first year that adult vaccine sales overtook

> pediatric sales, just slightly but significantly

> nonetheless. Adult vaccines represented 44% of

> total vaccine sales in 2006. By 2007, sales

> attributed to adult doses rose to 50.6% of

> vaccine sales. This surprising development can be

> attributed to robust sales of a group of

> influenza vaccines and the success of one

> product­Merck & Co.’s Gardasil for the HPV virus,

> which posted sales of $1.5 billion in 2007.

>

> World sales of adult vaccines exceeded $8.2

> billion in 2007, increasing 51.0% over 2006 sales

> of $5.4 billion. Sales of adult vaccines are

> projected to increase at a compound annual rate

> of 12.0% from 2008 to 2013 and reach $17.6 billion in 2013.

>

> Last year’s result could be written off as a

> one-time occurrence explained by the higher cost

> of adult vaccines (Gardasil carries an estimated

> price tag of $300–$500), and indeed adult

> vaccines are not expected to maintain the

> leadership position as competition and volume

> reduce adult vaccine prices. Yet the sudden show

> of strength by the adult segment portends a

> future where the segments will roughly equal out.

>

> The success of Gardasil and adult influenza

> vaccines has not only shaken up the market

> place­vaulting Merck from an estimated fourth

> place to a leadership role in the vaccine market

> in two years­but it has also created a tremendous

> opportunity for vaccine marketing. It is likely

> that the pharmaceutical industry will look to new

> adult vaccines for the next blockbuster drug.

> This may result in products in disease areas that

> were not treated by vaccines in the past.

>

> In 2007, the world market for preventive vaccines

> totaled $16.3 billion, up more than 38% from

> $11.7 billion in 2006. The market is predicted to

> increase at a compound annual rate of 13.1%

> during 2008. This growth rate is unheard of in

> other drug categories, especially since this is

> expected to be a challenging year for the

> pharmaceutical industry. Few other drug

> categories will see as many new product

> introductions and such public-policy attention.

>

> The world vaccines market is dominated by five

> companies: Merck & Co., GlaxoKline, Sanofi

> Pasteur, Wyeth, and Novartis. The four largest

> firms, whose reported vaccine sales exceeded $2

> billion each in 2007, held a combined 91.5% of the market.

>

> In 2007, Merck was the leading competitor with

> 26.2% market share, followed closely by Sanofi

> Pasteur with 25.9% and GlaxoKline with

> 24.2%. Wyeth followed at a distance with 15.2%,

> while Novartis held at 5.8%. In 2007, Novartis

> reported strong growth in its new vaccines and

> diagnostics division, with total sales of almost

> $1.5 billion on expanded usage of vaccines for

> tick-borne encephalitis, seasonal influenza, and pediatric

> immunizations.

>

> Pediatric Vaccines

>

> While adult vaccine revenues have grown more

> dramatically, there has been no letdown in sales

> of pediatric vaccines. Increased vaccination and

> new products will continue to drive growth in this category.

>

> Global vaccination rates will continue to rise,

> but wide discrepancies will remain from region to

> region. In 2007, almost 30 million infants

> worldwide had not been vaccinated against DPT3,

> with 75% of those living in India, China,

> Nigeria, Indonesia, Pakistan, Ethiopia, Congo,

> Sudan, Bangladesh, and the Philippines.

>

> In 2007, global sales of pediatric vaccines

> exceeded $8.0 billion, an increase of 25.2% over

> 2006 sales of $6.3 billion. This high growth was

> due in part to continued heavy gains of Wyeth’s

> pneumococcal vaccine, Prevnar during the year, as

> well as the introduction of Merck’s, RotaTeq.

>

> From 2007 to 2012, sales of Prevnar are expected

> to follow a more moderate growth rate, although

> new pneumococcal vaccines will be introduced that

> could stimulate further gains. This will result

> in an overall market expansion of 14.2% per year

> from 2008 to 2013, with total sales reaching

> $18.8 billion at the end of the forecast period.

>

> --------------------------------------------------------

> Sheri Nakken, former R.N., MA, Hahnemannian Homeopath

> Vaccination Information & Choice Network, Nevada City CA & Wales UK

> Vaccines - http://www.wellwithin1.com/vaccine.htm

> Vaccine Dangers & Homeopathy Online/email courses

>

>

>

>